secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000950170-22-016862
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q2 revenue $17.2M (+37% YoY); net loss $23.8M; FY22 guidance $68-72M
--------------------------------------------------------------------------------

- Surgical Glaucoma revenue $15.9M (+33% YoY); Dry Eye revenue $1.3M (+143% YoY).
- Gross margin expanded to 84% from 82% YoY on manufacturing cost reductions.
- Operating expenses rose 75% to $37.4M, driven by personnel and R&D investment.
- Cash and equivalents $220.1M; total debt $33.0M as of June 30, 2022.
- Full-year 2022 revenue guidance: $68-72M, representing 39-47% growth over 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017022016862/0000950170-22-016862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017022016862/sght-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-016862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer